Are you Dr. Fogelman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 110 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Unit 426
Houston, TX 77030Phone+1 713-792-2828Fax+1 713-745-1163
Summary
- Dr. David Fogelman, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Oklahoma, and New York. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2001 - 2004
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1998 - 2001
Albert Einstein College of MedicineClass of 1998
Certifications & Licensure
NY State Medical License 1999 - Present
TX State Medical License 2007 - 2026
OK State Medical License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Minocycline Study in Pancreatic Cancer Patients Start of enrollment: 2013 Jan 28
- Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 2020 Feb 01
Publications & Presentations
PubMed
- 8 citationsPembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.Takayuki Yoshino, Thierry Andre, Tae Won Kim, Wei Peng Yong, Kai-Keen Shiu
Cancer Science. 2023-03-01 - 29 citationsSingle-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.Aislyn Schalck, Donastas Sakellariou-Thompson, Marie-Andrée Forget, Emi Sei, Tara G Hughes
Cancer Discovery. 2022-10-05 - 1 citationsAssociation of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.Jennifer S Davis, Janelle C Chavez, Melissa Kok, Yazmin San Miguel, Hwa Young Lee
JAMA Network Open. 2022-10-03
Press Mentions
Phase I Study of DFP-11207, a Novel Oral Fluoropyrimidine with Reasonable AUC and Low Cmax and Improved Tolerability, in Patients with Solid TumorsMay 6th, 2020
Pancreatic Cancer Symptoms and SignsMarch 7th, 2019
Professional Memberships
- Member
